Literature DB >> 21590050

p53 nuclear accumulation in preneoplastic lesions and stage I uterine endometrioid adenocarcinoma.

F Buttitta1, A Marchetti, S Athanassiadou, A Gadducci, S Bellina, S Cosio, F Mancini, A Genazzani, G Bevilacqua.   

Abstract

A total of 118 endometrial neoplastic and preneoplastic lesions comprising 43 uterine endometrioid adenocarcinoma at stage I, 40 complex (adenomatous) hyperplasias and 35 atypical hyperplasias were examined for p53 nuclear accumulation to assess the incidence of p53 alterations in infiltrating carcinomas and to verify if p53 aberrations may allow the identification of a subset of premalignant cases with high risk of progression. No specific immunostaining was observed in the cases of complex hyperplasia without atypias. One (3%) of 35 atypical hyperplasias showed focal areas of p53 immuno-reactivity. The overall frequency of p53 overexpression in endometrial carcinomas was 54%. The distribution of cases with nuclear accumulation of p53 was significantly different (p=0.01) in tumours with different degree of invasiveness. In addition, p53 nuclear accumulation was observed more often in tumours with moderate (G2) or poor differentiation (G3) (p=0.03). Our data indicate that p53 aberrations are not early events in endometrial carcinogenesis and may be related with tumour progression and aggressiveness.

Entities:  

Year:  1997        PMID: 21590050     DOI: 10.3892/or.4.2.315

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  1 in total

1.  Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development.

Authors:  Allison Jones; Andrew E Teschendorff; Quanxi Li; Jane D Hayward; Athilakshmi Kannan; Tim Mould; James West; Michal Zikan; David Cibula; Heidi Fiegl; Shih-Han Lee; Elisabeth Wik; Richard Hadwin; Rupali Arora; Charlotte Lemech; Henna Turunen; Päivi Pakarinen; Ian J Jacobs; Helga B Salvesen; Milan K Bagchi; Indrani C Bagchi; Martin Widschwendter
Journal:  PLoS Med       Date:  2013-11-12       Impact factor: 11.069

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.